Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: A literature-based pooled analysis of randomized controlled trials

Lung

Volumn 190, Issue 4, 2012, Pages 355-364

  Inoue, Kouichi ^a   Narukawa, Mamoru ^a   Takeuchi, Masahiro ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Add on combination chemotherapy; Non small cell lung cancer; Overall survival; Pooled analysis; Randomized, controlled trial; Safety

Indexed keywords

ANTINEOPLASTIC AGENT;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; LUNG NON SMALL CELL CANCER; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84864363729     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9379-7     Document Type: Review

References (80)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Shepherd FA (1993) Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 5:310-322 (Pubitemid 23111775)
3. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology (2011) non-small cell lung can-cer, Version 3
4. Carter SK, Bakowski MT, Hellmann K (1987) Chemotherapy of cancer, 3rd edn. Wiley, Cheichster
5. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F et al (2003) Chemotherapy for elderly patients with advanced non-smal L-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372 (Pubitemid 36395256)
6. Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G et al (2004) Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91:489-497 (Pubitemid 39093568)
7. Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S et al (2006) Randomized phase II trial of docetaxel/ irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 24:4825-4832 (Pubitemid 46630908)
8. Comella P, Filippelli G, De Cataldis G, Massidda B, Frasci G, Maiorino L et al (2007) Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomized trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18:324-330 (Pubitemid 46323101)
9. Gebbia V, Gridelli C, Verusio C, Frontini L, Aitini E, Daniele B et al (2009) Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer 63:251-258
10. Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D et al (2010) A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68:420-426
11. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529-2536 (Pubitemid 30432518)
12. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F et al (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390-3399
13. O'Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R et al (2000) A randomized phase II study of SRL172 (Myco-bacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesotheli-oma. Br J Cancer 83:853-857
14. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130 (Pubitemid 30036345)
15. Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J et al (2000) Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 83:1128-1135
16. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P et al (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapaz-amine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18:1351-1359 (Pubitemid 30159856)
17. Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y et al (2002) A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis ofprognostic factors. Lung Cancer 36:313-319 (Pubitemid 34497133)
18. Souquet PJ, Tan EH, Rodrigues Pereira J, Van Klaveren R, Price A, Gatzemeier U et al (2002) GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 13:1853-1861 (Pubitemid 36040773)
19. Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C et al (2003) Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21:3207-3213 (Pubitemid 46606251)
20. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N et al (2003) Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335-341 (Pubitemid 36308141)
21. Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E et al (2004) Irinotecan plus gemcita-bine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 91:482-488 (Pubitemid 39093567)
22. Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chand-rinos V, Tsaroucha E et al (2004) Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 22:2602-2609 (Pubitemid 41103747)
23. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 1. J Clin Oncol 22:777-784 (Pubitemid 41103588)
24. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 2. J Clin Oncol 22:785-794 (Pubitemid 41103589)
25. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nem-unaitis JJ, Jablons DM et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191 (Pubitemid 41095154)
26. Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C et al (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss lung cancer study group. J Clin Oncol 22: 2348-2356 (Pubitemid 41115391)
27. O'Brien ME, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, Von Pawel J et al (2004) SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 15:906-914 (Pubitemid 39004346)
28. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M et al (2005) Phase III study of matrix metallopro-teinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23:842-849 (Pubitemid 46224184)
29. Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J et al (2005) Second-line treatment with iri-notecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 93:763-769 (Pubitemid 41486435)
30. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclit-axel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
31. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A et al (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung can-cer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23:2831-2839 (Pubitemid 46179474)
32. Lilenbaum RC, Herndon JE II, List MA, Desch C, Watson DM, Miller AA et al (2005) Single-agent versus combination che-motherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23:190-196 (Pubitemid 41702638)
33. Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Niko-laou M, Gaglia A et al (2005) Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16:294-299 (Pubitemid 40309313)
34. Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R et al (2005) Phase III trial of gemcitabine plus car-boplatin versus single-agent Gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23:8380-8388
35. Vansteenkiste J, Canon JL, Riska H, Pirker R, Peterson P, John W et al (2005) Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs 23:263-269 (Pubitemid 40684953)
36. Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA et al (2005) A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92:15-20 (Pubitemid 40188429)
37. Williamson SK, Crowley JJ, Lara PN Jr, Mc Coy J, Lau DH, Tucker RW et al (2005) Phase III trial of paclitaxel plus carbo-platin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest oncology group trial S0003. J Clin Oncol 23:9097-9104
38. Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I et al (2006) Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study. Invest New Drugs 24:241-248 (Pubitemid 43738962)
39. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP et al (2006) Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24: 5025-5033 (Pubitemid 46631406)
40. Paccagnella A, Oniga F, Bearz A, Favaretto A, Clerici M, Barbieri F et al (2006) Adding gemcitabine to paclitaxel/carbo-platin combination increases survival in advanced non-small-cell lung cancer: results ofaphase II-III study. J Clin Oncol 24:681-687 (Pubitemid 46630434)
41. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM et al (2006) Phase III study of gemcitabine and cis-platin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 24:1428-1434 (Pubitemid 46622009)
42. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
43. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A et al (2006) Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 24:688-694 (Pubitemid 46630435)
44. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y et al (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin corrected, with or without cetux-imab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25:5777-5784
45. Chen YM, Liu JM, Chou TY, Perng RP, Tsai CM, Whang-Peng J (2007) Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adeno-carcinoma of the lung who failed at least 2 regimens of chemo-therapy. Cancer 109:1821-1828 (Pubitemid 46668546)
46. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 25:1545-1552 (Pubitemid 46733081)
47. Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F et al (2007) Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8:500-512 (Pubitemid 46805905)
48. Hainsworth JD, Spigel DR, Farley C, Shipley DL, Bearden JD, Gandhi J et al (2007) Weekly docetaxel versus docetaxel/gem-citabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie pearl cancer research network. Cancer 110:2027-2034 (Pubitemid 350036863)
49. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M et al (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25:4270-4277 (Pubitemid 47548567)
50. Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM et al (2008) Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 26:1879-1885
51. Chen YM, Perng RP, Shih JF, Whang-Peng J (2008) A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. Lung Cancer 61:214-219
52. Chou KT, Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J (2008) Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. Lung Cancer 59:64-68
53. Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A et al (2008) Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 59:57-63
54. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE et al (2008) Randomized phase II study of vand-etanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407-5415
55. Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G et al (2008) Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in com-bination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3979-3986
56. Mc Keage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R et al (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99:2006-2012
57. Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M et al (2008) Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vino-relbine in chemotherapy-naive patients with advanced or meta-static non-small-cell lung cancer: SPIRIT I. J Clin Oncol 26:1886-1892
58. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E et al (2008) A phase II study of Tg4010 (Mva-Muc1-Il2) in associa-tion with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 3:735-744
59. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC et al (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/ vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19:362-369 (Pubitemid 351201721)
60. Lee SM, Rudd R, Woll PJ, Ottensmeier C, Gilligan D, Price A et al (2009) A. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:5248-5254
61. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A et al (2009) A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 4:1002-1009
62. Novello S, Falcone A, Crinò L, Rinaldi M, Nardi M, De Marinis F et al (2009) Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer 66:327-332
63. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525-1531
64. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM et al (2009) Randomized phase II and Pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038-2045
65. Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S et al (2009) Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan clinical oncology group trial (JCOG0104). Ann Oncol 20:835-841
66. Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E, Villanueva-Rodráguez G, Cerón-Lizárraga TL, Martínez-Barrera L et al (2010) Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3463-3471
67. Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J et al (2010) Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier oncology group LUN06-116. J Thorac Oncol 5:1815-1820
68. Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A et al (2010) Phase II, double-blinded, randomized study of en-zastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 5:369-375
69. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D et al (2010) Randomized, double-blind trial of carbo-platin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55
70. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C et al (2010) Vandetanib plus docetaxel versus docetaxel as sec-ond-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11:619-626
71. Lynch TJ, Patel T, Dreisbach L, Mc Cleod M, Heim WJ, Hermann RC et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917
72. Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N et al (2010) A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer 10:633
73. Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ (2010) Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67:330-338
74. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B et al (2010) Carboplatin and Paclitaxel in combi-nation with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56-62
75. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M et al (2010) Phase III study of carboplatin and pac-litaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842
76. Schiller JH, von Pawel J, Schütt P, Ansari RH, Thomas M, Saleh M et al (2010) Pemetrexed with or without matuzumab as sec-ond-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5:1977-1985
77. Segawa Y, Kiura K, Hotta K, Takigawa N, Tabata M, Matsuo K et al (2010) A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama lung cancer study group (OLCSG) Trial 0503. J Thorac Oncol 5:1430-1434
78. Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D et al (2010) Randomized, phase II trial ofpemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5:1963-1969
79. Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF (2010) Safety and efficacy of combining sunitinib with bev-acizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 5:354-360
80. Zwitter M, Kovac V, Rajer M, Vrankar M, Smrdel U (2010) Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial. Anticancer Drugs 21:662-668